DIAOPTIM MR 60 MG 30 TAB

Indications

Approved Uses

Type 2 diabetes mellitus in adults when diet, physical exercise, and weight reduction alone are insufficient.

Dosage & Administration

Dosing by Condition

Type 2 diabetes mellitus (modified-release): start 30 mg once daily with breakfast; titrate by 30 mg increments to usual maintenance 30-120 mg once daily; maximum 120 mg once daily.

Initial Dose

30 mg once daily, taken with breakfast.

Maintenance Dose

30-120 mg once daily.

Maximum Dose

120 mg once daily

Children's Dosage

Not approved for children.

How to Take

Take once daily with breakfast (or the first main meal); swallow the modified-release tablet whole with water; do not crush or chew (splitting only if the specific product is scored and the local label allows).

Drug Interactions

Food Interaction

Take with breakfast/food and maintain regular carbohydrate intake; do not skip meals after dosing to reduce hypoglycemia risk.

Special Populations

Children

Not approved for children.

Elderly

Start at lowest dose (30 mg once daily), titrate cautiously with close blood glucose monitoring due to increased risk of hypoglycemia; standard maximum dose applies but caution is warranted

Storage & Patient Advice

Patient Counseling

Take 1 modified‑release tablet once daily with breakfast (or the first main meal); do not skip or delay meals after taking it. Swallow whole-do not crush, chew, or split. Monitor blood glucose as directed and keep regular follow‑up for HbA1c/renal/hepatic review. Know and treat hypoglycemia (sweating, tremor, hunger, palpitations, confusion): carry fast‑acting glucose and recheck; seek help if severe or recurrent. Avoid or limit alcohol (increases risk of hypoglycemia). Tell your clinician/pharmacist about all medicines (e.g., other antidiabetics, warfarin, azole antifungals, macrolides, NSAIDs) and do not stop therapy without medical advice.

Pharmacology

Onset of Action

Modified-release: peak plasma concentrations typically occur about 6-12 hours after dosing; glucose-lowering effect begins within hours but is not best characterized as a 2-3 hour peak for MR.

Duration of Effect

Approximately 24 hours (modified-release).

Bioavailability

Approximately 97% (high oral bioavailability).

Product Information

Available Dosage Forms

Immediate-release tablet and modified-release tablet (formulations vary by market/brand).

Composition per Dose

Each modified-release tablet: 60 mg gliclazide

Generic Availability

Yes

OTC Alternatives

No OTC alternative

Diabetes Type

Type 2

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.